Isavuconazonium sulfate for the treatment of fungal infection

R. C. Walker, J. D. Zeuli, Z. Temesgen

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Isavuconazole is a new azole antifungal drug with a broad antifungal spectrum that includes yeasts, molds and dimorphic fungi. Its prodrug, isavuconazonium sulfate, is currently approved in the United States and Europe for the treatment of the two of the most common and most challenging invasive fungal infections in clinical practice, invasive aspergillosis and invasive mucormycosis. It is available in both oral and intravenous formulations for once-a-day dosing and has favorable safety profile and drug interaction potential in comparison to voriconazole. Its role in the treatment of other fungal infections, besides aspergillosis and mucormycosis, remains to be determined. Similarly, its efficacy in prophylaxis against invasive fungal infections or its utility in patients with prior azole exposure is yet to be elucidated in clinical studies.

Original languageEnglish (US)
Pages (from-to)7-16
Number of pages10
JournalDrugs of Today
Issue number1
StatePublished - Jan 2016


  • Antifungal
  • BAL-8557
  • Isavuconazole
  • Isavuconazonium sulfate
  • Triazole

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Isavuconazonium sulfate for the treatment of fungal infection'. Together they form a unique fingerprint.

Cite this